And just like that, the global race to advance a COVID-19 vaccine got turned up a notch. On Monday, mRNA specialist Moderna (MRNA) announced positive data regarding its COVID-19 vaccine candidate, mRNA-1273.5-star Oppenheimer’s Hartaj Singh applauds Moderna’s “unprecedented pace of development” and highlights the vaccine’s potential to accelerate the mRNA platform’s progress. In the first stage of the Phase 1 study across three different dose groups (25, 100, 250 µg), following the analysis of eight patients’ data, all developed neutralizing antibodies which stopped the virus from replicating. Additionally, the study showed the vaccine was safe, and that the …read more
Source:: Yahoo Finance
